Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DNAAF3 antisense RNA 1 (DNAAF3-AS1) is a human long noncoding RNA (lncRNA) gene located on chromosome 19. It is transcribed in the antisense orientation relative to the DNAAF3 gene, which encodes a protein critical for axonemal dynein assembly and ciliary function[2][3][4]. DNAAF3-AS1 has been classified as a cis-repressor lncRNA, meaning it can repress the expression of neighboring genes, potentially acting on the same chromosome region where it is transcribed[6]. Diseases associated with DNAAF3-AS1 include ciliary dyskinesia, both primary and type 2, which are likely linked to its genomic context and potential regulatory impact on DNAAF3 or related genes[3]. There are no known drug interactions, no established roles as a biomarker, and no evidence that DNAAF3-AS1 itself is a direct therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNAAF3 antisense RNA 1 (DNAAF3-AS1).